Positive News SentimentPositive NewsNASDAQ:TENX Tenax Therapeutics (TENX) Stock Price, News & Analysis $2.04 -0.09 (-4.27%) As of 10:11 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Tenax Therapeutics Stock (NASDAQ:TENX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tenax Therapeutics alerts:Sign Up Key Stats Today's Range$2.01▼$2.1450-Day Range$1.38▼$18.3252-Week Range$1.31▼$19.40Volume859,552 shsAverage Volume2.17 million shsMarket Capitalization$76.30 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Tenax Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications. Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials. Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.AI Generated. May Contain Errors. Read More Tenax Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreTENX MarketRank™: Tenax Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 132nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingTenax Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialTenax Therapeutics has a consensus price target of $14.00, representing about 557.3% upside from its current price of $2.13.Amount of Analyst CoverageTenax Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tenax Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tenax Therapeutics are expected to decrease in the coming year, from ($1.38) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenax Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenax Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Tenax Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.40% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 0.41, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenax Therapeutics has recently increased by 114.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment1.52 News SentimentTenax Therapeutics has a news sentiment score of 1.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Tenax Therapeutics this week, compared to 3 articles on an average week.Search Interest14 people have searched for TENX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tenax Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $4,800,222.00 in company stock, which represents 6.0225% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,800,222.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.81% of the stock of Tenax Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.67% of the stock of Tenax Therapeutics is held by institutions.Read more about Tenax Therapeutics' insider trading history. Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TENX Stock News HeadlinesAdar1 Capital Management, Llc Buys 900,000 Shares of Tenax Therapeutics (NASDAQ:TENX) StockSeptember 10 at 4:09 AM | americanbankingnews.comTenax Therapeutics (NASDAQ:TENX) Major Shareholder Buys $1,602,000.00 in StockSeptember 9 at 4:21 AM | insidertrades.comShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percent run, and Nvidia before it climbed more than 50,000 percent. Now Chaikin says a new AI data center technology using 99 percent less electricity, water, and space could accelerate scientific breakthroughs 360-fold, and one company behind it just flashed bullish in his system. See the full research and the ticker Chaikin is watching before this presentation goes offline.September 10 at 1:00 AM | Chaikin Analytics (Ad)Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 9 at 3:44 AM | americanbankingnews.comTenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?September 4, 2026 | insidermonkey.comInsider Buying: Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Purchases $322,304.40 in StockSeptember 3, 2026 | insidertrades.comGuggenheim downgrades Tenax Therapeutics (TENX)September 2, 2026 | msn.comTenax Therapeutics (NASDAQ:TENX) Major Shareholder Acquires 107,374 SharesAugust 25, 2026 | insidertrades.comSee More Headlines TENX Stock Analysis - Frequently Asked Questions How have TENX shares performed this year? Tenax Therapeutics' stock was trading at $12.19 at the beginning of 2026. Since then, TENX shares have decreased by 82.5% and is now trading at $2.13. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) released its quarterly earnings data on Friday, July, 31st. The specialty pharmaceutical company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.03. When did Tenax Therapeutics' stock split? Tenax Therapeutics's stock reverse split before market open on Wednesday, January 3rd 2024.The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. Who are Tenax Therapeutics' major shareholders? Top institutional shareholders of Tenax Therapeutics include Braidwell LP (1.56%), Bank of New York Mellon Corp (1.23%), Wellington Management Group LLP (0.26%) and Squarepoint Ops LLC (0.09%). Insiders that own company stock include Adar1 Capital Management, Llc, Stuart Rich, Christopher Thomas Giordano and Thomas Mcgauley. View institutional ownership trends. How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenax Therapeutics investors own include Sangamo Therapeutics (SGMO), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Novo Nordisk A/S (NVO). Company Calendar Last Earnings7/31/2026Today9/10/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TENX's financial health is in the Red zone, according to TradeSmith. TENX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TENX CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees9Year Founded1967Price Target and Rating Average Price Target for Tenax Therapeutics$14.00 High Price Target$50.00 Low Price Target$4.00 Potential Upside/Downside+591.4%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.54% Return on Assets-57.42% Debt Debt-to-Equity RatioN/A Current Ratio15.07 Quick Ratio15.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.42 per share Price / Book0.19Miscellaneous Outstanding Shares37,420,000Free Float33,378,000Market Cap$75.78 million OptionableNot Optionable Beta0.83 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TENX) was last updated on 9/10/2026 by MarketBeat.com Staff. From Our PartnersGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredShocking AI prediction from the “Billionaire Whisperer"Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredWashington Is Broke—Could YOUR Savings Be Next?The Department of Justice recently argued in court that cash is not legally property, raising new questions fo...Priority Gold | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | SponsoredThe $8,000 Gold Call Every Retirement Saver Needs to Read Right NowGold didn't creep higher—it broke $5,000, a level many analysts thought would hold. Now JPMorgan, the biggest ...Golden Crest Metals | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TENX Stock Alerts